Abbott Laboratories Q2 Earnings: Dividends Don't Lie

Abbott Laboratories (ABT) reported Q2 normalized EPS of $1.26 (in-line) and revenue of $11.14B (slight beat), driven by strong Medical Device growth which offset a decline in Diagnostics due to reduced COVID-19 testing and China pressures. While the stock has seen significant price appreciation leading to higher P/E ratios, and faces macroeconomic uncertainties including potential drug price controls and tariffs (estimated $700M impact from fading COVID-19 demand and $200M in FY25 tariff costs), the author reiterates a 'buy' rating. This is based on ABT's perceived intact long-term moat, robust 7.2% annual dividend growth, and a current dividend yield of 1.76% which suggests a fair valuation despite near-term challenges.

Analysis

Abbott Laboratories (ABT) reported in-line FQ2 normalized EPS of $1.26 on revenue of $11.14 billion, a slight beat driven by strong performance in its Medical Device segment, which grew 13%. This growth, fueled by double-digit gains in diabetes care and structural heart products, was offset by a 1% decline in the Diagnostics segment, primarily due to reduced demand for COVID-19 tests and volume-based procurement pressures in China. Despite recent stock price appreciation that has pushed its Non-GAAP TTM P/E to 26.95—a 66% premium to the sector median—the company's valuation is viewed as fair when measured by its dividend yield of 1.76%, which is close to its 10-year average of 1.81%. However, ABT faces significant macroeconomic headwinds, including an estimated $700 million top-line impact from fading COVID demand and China pricing, plus a projected $200 million in tariff-related costs for FY25. The outlook is further clouded by potential US drug price controls and 19 downward EPS revisions versus only 3 upward, suggesting tempered near-term expectations. The company's declared dividend growth of 7.2% is presented as a key indicator of its durable long-term moat amidst these uncertainties.

Key Decisions for Investors

• Investors could look past the elevated P/E ratio and consider the stock's 1.76% dividend yield, which is near historical averages, as a more reliable indicator of fair valuation amidst market uncertainty.
• It is critical to monitor geopolitical developments, specifically potential US drug price legislation and tariff escalations, which represent quantifiable risks with an estimated $200 million cost impact for FY25.
• Focus on future segment performance, particularly whether the Medical Device division's 13% growth momentum can continue to offset the structural decline in Diagnostics sales related to COVID-19 testing and pressures in China.
• Given the 19 downward earnings revisions, investors should be prepared for potential near-term volatility and muted sequential earnings growth as guided by the company.